Remotely Controlled Miniature Biological Robots Could Be Used for MIS and Detection of Disease Biomarkers
|
By LabMedica International staff writers Posted on 23 Jan 2023 |

A team of researchers has developed remotely controlled miniature biological robots that could find potential applications in medicine, such as minimum invasive surgery or detection of cancer within the human body.
The hybrid “eBiobots” are the first to combine soft materials, living muscle and microelectronics, according to researchers at the University of Illinois Urbana-Champaign (Champaign, IL, USA), Northwestern University (Evanston, IL, USA) and collaborating institutions. They have described their centimeter-scale biological machines in the journal Science Robotics.
Researchers at the University of Illinois Urbana-Champaign had earlier developed biobots, which are small biological robots powered by mouse muscle tissue grown on a soft 3D-printed polymer skeleton. In 2012, the team had demonstrated walking biobots. In 2016, they had also demonstrated light-activated biobots which provided the researchers with some control. However, the inability to deliver the light pulses to the biobots outside of a lab setting limited their practical applications. This time, researchers at Northwestern University helped integrate tiny wireless microelectronics and battery-free micro-LEDs, allowing them to remotely control the eBiobots.
With the aim of providing freedom of movement to the biobots in order to make them suitable for practical applications, the researchers focused on eliminating bulky batteries and tethering wires. The eBiobots use a receiver coil to harvest power and provide a regulated output voltage to power the micro-LEDs. The researchers are able to send a wireless signal to the eBiobots that prompts the LEDs to pulse. The LEDs stimulate the light-sensitive engineered muscle to contract, moving the polymer legs so that the machines can “walk.” The micro-LEDs are so targeted in a way that they can activate specific portions of muscle, making the eBiobot turn in the desired direction.
Using computational modeling, the researchers optimized the eBiobot design and integrated the components for robustness, speed and maneuverability. The iterative design and additive 3D printing of the scaffolds enabled rapid cycles of experiments and improvement in performance, according to the researchers. The design offers potential for future integration of additional microelectronics, such as chemical and biological sensors, or 3D-printed scaffold parts for functions like pushing or transporting things that the biobots can encounter. The integration of electronic sensors or biological neurons could allow the eBiobots to sense and respond to biomarkers for disease, among other possibilities.
“Integrating microelectronics allows the merger of the biological world and the electronics world, both with many advantages of their own, to now produce these electronic biobots and machines that could be useful for many medical, sensing and environmental applications in the future,” said study co-leader Rashid Bashir, an Illinois professor of bioengineering and dean of the Grainger College of Engineering.
“In developing a first-ever hybrid bioelectronic robot, we are opening the door for a new paradigm of applications for health care innovation, such as in-situ biopsies and analysis, minimum invasive surgery or even cancer detection within the human body,” said co-first author Zhengwei Li, an assistant professor of biomedical engineering at the University of Houston.
Related Links:
University of Illinois Urbana-Champaign
Northwestern University
Latest Technology News
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more







